Renaissance Technologies
CHRS icon

Renaissance Technologies’s Coherus Oncology CHRS Stock Holding History

Renaissance Technologies’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$561K Buy
331,700
+193,800
+141% +$344K ﹤0.01% 2557
2025
Q4 		$196K Buy
137,900
+113,800
+472% +$166K ﹤0.01% 2890
2025
Q3 		$39.5K Sell
24,100
-498,825
-95% -$555K ﹤0.01% 3369
2025
Q2 		$382K Buy
522,925
+12,297
+2% +$10.6K ﹤0.01% 2962
2025
Q1 		$412K Buy
+510,628
New +$588K ﹤0.01% 2818
2024
Q4 		– Sell
-432,068
Closed -$449K – 3602
2024
Q3 		$449K Buy
432,068
+37,240
+9% +$51.1K ﹤0.01% 2836
2024
Q2 		$683K Buy
394,828
+242,500
+159% +$488K ﹤0.01% 2535
2024
Q1 		$364K Buy
+152,328
New +$375K ﹤0.01% 3002
2022
Q4 		– Sell
-52,800
Closed -$507K – 4138
2022
Q3 		$507K Sell
52,800
-152,700
-74% -$1.55M ﹤0.01% 2928
2022
Q2 		$1.49M Buy
205,500
+41,400
+25% +$360K ﹤0.01% 2418
2022
Q1 		$2.12M Buy
164,100
+108,300
+194% +$1.38M ﹤0.01% 2192
2021
Q4 		$891K Buy
+55,800
New +$976K ﹤0.01% 2736
2021
Q2 		– Sell
-230,700
Closed -$3.37M – 3486
2021
Q1 		$3.37M Sell
230,700
-30,500
-12% -$518K ﹤0.01% 1897
2020
Q4 		$4.54M Buy
261,200
+179,300
+219% +$3.19M ﹤0.01% 1657
2020
Q3 		$1.5M Sell
81,900
-324,200
-80% -$6.03M ﹤0.01% 2286
2020
Q2 		$7.25M Buy
406,100
+326,200
+408% +$5.52M 0.01% 1408
2020
Q1 		$1.3M Sell
79,900
-48,100
-38% -$889K ﹤0.01% 2293
2019
Q4 		$2.31M Buy
+128,000
New +$2.36M ﹤0.01% 2254
2018
Q4 		– Sell
-17,100
Closed -$282K – 3396
2018
Q3 		$282K Buy
+17,100
New +$303K ﹤0.01% 3039
2017
Q3 		– Sell
-21,900
Closed -$314K – 3211
2017
Q2 		$314K Sell
21,900
-91,300
-81% -$1.76M ﹤0.01% 2890
2017
Q1 		$2.39M Buy
+113,200
New +$2.78M ﹤0.01% 2141
2016
Q3 		– Sell
-94,500
Closed -$1.6M – 3338
2016
Q2 		$1.6M Buy
+94,500
New +$1.77M ﹤0.01% 2325
2015
Q4 		– Sell
-85,500
Closed -$1.71M – 3286
2015
Q3 		$1.71M Buy
85,500
+44,593
+109% +$1.36M ﹤0.01% 2096
2015
Q2 		$1.18M Buy
+40,907
New +$1.03M ﹤0.01% 2359

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Renaissance Technologies's CHRS Position: Q1 2026 in Review

Renaissance Technologies increased its Coherus Oncology (CHRS) stake by 141% in Q1 2026, buying an estimated $344K and bringing the position to 331,700 shares worth $561K. The position accounts for ﹤0.01% of the portfolio, ranked #2557.

Renaissance Technologies first reported a position in CHRS in Q2 2015 and has held it in 24 quarters since. The position peaked at $7.25M in Q2 2020. 157 funds tracked by Wall St. Rank hold CHRS as of Q1 2026.

  • Renaissance Technologies held 331,700 shares of Coherus Oncology worth $561K as of Q1 2026.
  • Renaissance Technologies bought 193,800 Coherus Oncology shares in Q1 2026, an estimated $344K.
  • Coherus Oncology made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #2557 holding.
  • Renaissance Technologies first reported a position in Coherus Oncology in Q2 2015 and has held it in 24 quarters since.
  • Renaissance Technologies's Coherus Oncology position peaked at $7.25M in Q2 2020.
  • 157 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.